Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01

Known as: FF-10501, FF-10501-01, IMPDH Inhibitor FF-10501 
An orally bioavailable inhibitor of inosine 5'- monophosphate dehydrogenase (IMPDH), with potential antineoplastic activity. Upon administration… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2018
0120082018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
One of the major symptoms of myelodysplastic syndromes (MDS) is severe cytopenia. Despite cytokine therapies, such as… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
BACKGROUND FF-10501-01 is a selective inosine monophosphate dehydrogenase (IMPDH) inhibitor that has shown activity in cancer… (More)
Is this relevant?
2016
2016
Resistance to azacitidine is a major issue in the treatments of myelodysplastic syndrome and acute myeloid leukemia, and previous… (More)
  • table 1
  • figure 2
  • figure 3
  • table 2
  • figure 4
Is this relevant?
2012
2012
MPA (mycophenolic acid) is an immunosuppressive drug produced by several fungi in Penicillium subgenus Penicillium. This toxic… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2008
2008
The objective of the study was to evaluate the effect of mycophenolate mofetil (MMF) on the regulation of inosine monophosphate… (More)
Is this relevant?